ADmit Therapeutics
Why do we like ADmit Therapeutics?
Problem
Alzheimer’s disease is one of the biggest healthcare challenges of our time. Its late diagnosis limits access to cognitive therapies that could slow its progression, and the difficulty in identifying early-stage patients hinders the development of effective treatments.
Solution
ADmit Therapeutics has developed an innovative blood test based on epigenetic markers and DNA sequencing, capable of detecting AD 5-7 years before clinical symptoms appear. This approach allows for earlier intervention and improves patient selection for clinical trials, increasing the chances of developing new treatments.
Impact
By enabling early diagnosis, ADmit Therapeutics can significantly reduce the prevalence of Alzheimer’s in the coming decades. Their solution shortens detection time, reduces healthcare costs, and improves patients’ quality of life while advancing research towards effective therapies.
Sector
- Prevention & Diagnosis
Headquarters
Spain
1st investment
2019